Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.80 |
| ▸ | GRM5 | P41594 | 1/20 | 0.73 |
| ▸ | NPC1 | O15118 | 1/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.66 |
| ▸ | BLM | P54132 | 1/20 | 0.66 |
| ▸ | HPGD | P15428 | 4/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.64 |
| ▸ | ACHE | P22303 | 1/20 | 0.62 |
| ▸ | USP2 | O75604 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10293599 | 0.93 | POLB (0.71) | POLBGRM5NPC1CYP2C9BLM | |
| SCHEMBL10724841 | 0.90 | POLB (0.81) | POLBGRM5NPC1HPGDKMT2A | |
| SCHEMBL252026 | 0.89 | HPGD (0.79) | POLBBLMHPGDKMT2AMEN1 | |
| SCHEMBL7129676 | 0.89 | HPGD (0.79) | POLBBLMHPGDKMT2AMEN1 | |
| SCHEMBL8158988 | 0.89 | POLB (1.00) | POLBGRM5NPC1CYP2C9HPGD | |
| Hydrochloric Acid SCHEMBL1597472 | 0.87 | HPGD (0.76) | POLBBLMHPGDKMT2AMEN1 | |
| SCHEMBL14980308 | 0.86 | POLB (0.72) | POLBGRM5NPC1CYP2C9HPGD | |
| SCHEMBL10723960 | 0.86 | HPGD (0.68) | POLBGRM5HPGDKMT2AMEN1 | |
| SCHEMBL14980324 | 0.85 | POLB (0.74) | POLBGRM5NPC1CYP2C9HPGD | |
| SCHEMBL3641190 | 0.85 | GRM5 (1.00) | POLBGRM5NPC1CYP2C9HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 207 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113135922-B | Azepane [4,3,2-cd ] isoindol-2-one derivatives and application thereof | 中国药科大学 | 2023-05-30 | — | — | CN | claimed |
| CN-101412708-A | Duloxetine derivative and preparation thereof | UNIV HEBEI TECHNOLOGY (CN) | 2009-04-22 | — | — | CN | claimed |
| WO-2024016826-A1 | 6-POSITION SUBSTITUTED DIHYDROBENZO[E][1,2,3]OXATHIAZINE 2,2-DIOXIDE COMPOUND, PREPARATION THEREFOR, AND USE THEREOF | 杭州市第七人民医院 | 2024-01-25 | — | — | WO | disclosed |
| EP-4273143-A1 | DERIVATIVE OF 2,5-DIKETOPIPERAZINE COMPOUND, AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | Dalian WZ Probiotics AD Health Co., Ltd (CN) | 2023-11-08 | — | — | EP | disclosed |
| US-20230348369-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230338546-A1 | ORAL FORMULATIONS OF KAPPA OPIOID RECEPTOR AGONISTS | CARA THERAPEUTICS INC (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230338546-A1 | ORAL FORMULATIONS OF KAPPA OPIOID RECEPTOR AGONISTS | CARA THERAPEUTICS INC (US) | 2023-10-26 | — | — | US | disclosed |
| EP-3262036-B1 | THERAPEUTIC PYRIDAZINE COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2023-09-13 | — | — | EP | disclosed |
| US-11684674-B2 | Oral formulations of kappa opioid receptor agonists | CARA THERAPEUTICS, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| US-20230183224-A1 | BEZOXAZINE DERIVATIVES USEFUL AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230165883-A1 | INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR TREATING CORONARY DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-06-01 | — | — | US | disclosed |
| WO-2007076161-A2 | COMPOUNDS WITH THERAPEUTIC ACTIVITY | MYRIAD GENETICS, INC (US) | 2007-07-05 | — | — | WO | disclosed |
| US-7037913-B2 | Piperazinyl derivatives of naphthalenes, (iso)quinolines and naphthyridines; used particularly the treatment of HIV and AIDS. | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-05-02 | — | — | US | disclosed |
| EP-1499319-A4 | BICYCLO 4.4.0 ANTIVIRAL DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2006-02-08 | — | — | EP | disclosed |
| EP-1499319-A1 | BICYCLO 4.4.0 ANTIVIRAL DERIVATIVES | Bristol-Myers Squibb Company (US) | 2005-01-26 | — | — | EP | disclosed |
| EP-1478645-A2 | QUINOLINONE DERIVATIVES FOR TREATING CELL PROLIFERATION RELATED DISORDERS | Amgen Inc. (US) | 2004-11-24 | — | — | EP | disclosed |
| US-20040009985-A1 | Bicyclo 4.4.0 antiviral derivatives | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2004-01-15 | — | — | US | disclosed |
| WO-2003092695-A1 | BICYCLO 4.4.0 ANTIVIRAL DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-11-13 | — | — | WO | disclosed |
| WO-2003066630-A2 | QUINOLINONE DERIVATIVES FOR TREATING CELL PROLIFERATION RELATED DISORDERS | AMGEN INC. (US) | 2003-08-14 | — | — | WO | disclosed |
| EP-0354303-A1 | Amidines of diphenyl sulfones, their derivatives and their use | AMERICAN CYANAMID COMPANY (US) | 1990-02-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183224-A1 | BEZOXAZINE DERIVATIVES USEFUL AS MONOACYLGLYCEROL LIPASE INHIBITORS | LPL, LIPC, PNLIP | POLB 3034/4885GRM5 1359/4885NPC1 127/4885 |
| US-20230348369-A1 | NAMPT MODULATORS | NAMPT, NNT, NAPRT | POLB 4018/4885GRM5 3035/4885NPC1 128/4885 |
| US-20230165883-A1 | INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR TREATING CORONARY DISORDERS | GCDH, HPGD, PGD | POLB 1169/4885GRM5 1835/4885NPC1 2200/4885 |
| US-20040009985-A1 | Bicyclo 4.4.0 antiviral derivatives | CCR5, ITPA, IL4 | POLB 562/4885GRM5 559/4885NPC1 524/4885 |
| US-20230338546-A1 | ORAL FORMULATIONS OF KAPPA OPIOID RECEPTOR AGONISTS | OPRK1, OPRL1, OGFR | POLB 3442/4885GRM5 717/4885NPC1 720/4885 |
| US-11684674-B2 | Oral formulations of kappa opioid receptor agonists | OPRK1, OPRL1, OGFR | POLB 3442/4885GRM5 717/4885NPC1 720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.